The only way we can tell if Tysabri is any better at reducing disability than CRABs is by trying to analyze it the same way it was done in the trials that used the CRABS (i.e., slicing it differently).
That's the problem...you can't slice it differently because the trials were designed differently. But Biogen tried to compare their trial results between Tysabri and the other MS meds and state that their results were better. As Bebe stated, you can't compare them. But in the world of marketing, that doesn't mean much as long as the people reading your press releases don't know any differently!
HarryZ, I thought you'd be happy - you were forever complaining that:
1.) There's no disability data
2.) They're not releasing the 2-year data.
3.) The FDA shouldn't have approved it, and the 2-year data will be different.
Not sure that I would use the word "complaining"...perhaps concerned about the incomplete data would be much better
1) The disability data I am looking for is the EDSS scores which I am told is the real measurement for these drugs. From what I have been told by people in MS medicine,that did not improve in the trials. Biogen has still not published that data yet.
2) I've never "complained" that Biogen didn't release the two year data....only the fact that it had not been released to give the MS peer group a chance to review it. It is now starting to come out, mind you not in publications as yet but in Biogen press releases.
3) I've never said the FDA should not have approved Tysabri...only that the approval of the drug based on one year data was very unordinary when it came to the approval of Tysabri. Almost every MS professional that I have spoken to or read comments about have all said the same thing! And when you look at the current situation that the FDA has found itself in with a variety of problems with other "approved" drugs, you have to wonder about their process with Tysabri.
Now, granted, I may be biased toward that drug, since it's my wife only real hope of staving off MS using current drugs.
But surely, isn't it time to express some joy at the good news?
With all the suffering that I have seen MS patients endure over the years, I, as much as anyone else affected by this disease, welcome any good news that helps people with this disease. At the same time there is nothing worse than promoting the heck out of a drug for any kind of illness before you have all your homework done. I've been told by a number of MS medical people that the homework was not completed and that this is not the process to follow when it comes to drug development. Who knows, perhaps in the long run, Tysabri will turn out to be an excellent drug for certain kinds of MS patients and the days of having to endure the problems associated with the CRABs will be greatly reduced.
As for Biogen's game plan...well, those in the field of medicine already know them and how they operate. Nothing more needs to be said.